| Autor: |
Gale, Robert Peter, Apperley, Jane |
| Zdroj: |
Current Hematologic Malignancy Reports; Dec2019, Vol. 14 Issue 6, p477-479, 3p |
| Abstrakt: |
Purpose of Review: Determine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers. Recent Findings: CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer have more heterogeneous phenotypes and extraordinarily greater genotypic diversity and mutational complexity. Summary: Lesions learned from treating CML have little applicability to other leukaemias, haematologic cancers or solid cancer. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink